(1 - 14 from 28
)
Puma Biotech shares jump after initial FDA review of cancer ...
www.reuters.com
22 May — Matthew Eckler, an analyst at RBC Capital Markets, said in a research note that he would be surprised if neratinib emerges completely ... › article
Why This Biotech Crashed Despite Topping Breast Cancer ...
www.investors.com
10 Nov — "Headed into (earnings), we sense that buy-side expectations around the launch were likely higher," RBC analyst Matthew Eckler wrote in a ... › news › technology › why-t...
Epatite B, dopo 25 anni Fda approva nuovo vaccino ...
www.pharmastar.it
12 Nov — Commentando l'approvazione, l'analista di RBC Capital Markets Matthew Eckler ha dichiarato: "la nostra lettura delle indicazioni ottenute ... › news › fda
Puma's early Nerlynx launch raises doubts of a takeover
www.biopharmadive.com
1 Aug — RBC analyst Matthew Eckler wrote in the July 31 note. “We'd tend to agree that if a deal was only days or weeks away, ... › news › pumas-early-...
sorted by relevance / date